We have three assets available for out-licensing in heart attack and cancer.
We are seeking partnerships to advance these assets further in development. Each
peptide therapeutic is focused on a hard-to-drug target for each of the
diseases. For all three assets we have statistically significant in vitro
and in vivo data.
First in Class Peptide Therapeutics Available for Licensing in Heart Attack and Cancer
- Interference peptides: block protein-protein interactions
- Bi-functional Degraders: block the protein signalling pathway and degrade the disease causing protein
We are also seeking partnerships to leverage our platform technologies in
protein-protein interference blockade, molecular glues and protein degradation
to develop novel peptides against targets identified by partners. Our platforms
are versatile and we can rapidly generate lead compounds for diverse diseases.
Yabao – K13
Our current partnership with Yabao Pharmaceutical is to advance the development and
commercialization of K13, an interference peptide that we developed for the
treatment of stroke. It has the potential to be the first- in-class PTEN-
targeting neuroprotective agent for stroke patients. Yabao has rights for China
only. We retain freedom to operate in the rest of the world.
Primedicine – PP-002
Our partnership with Primedicine is for the development and commercialization
of PP-002, an interference peptide that we developed targeting zD17/JNK as a
potential treatment for heart attack. Primedicine has rights for China only. We
retain freedom to operate in the rest of the world.